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Biologic degeneration of vein grafts after
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Objectives: To clarify the mechanism for poor patency of vein grafts after thrombectomy and the time limit for successful
salvage operation, we investigated the time course of biologic degenerative changes in thrombosed vein grafts.
Materials and Methods: The right femoral artery was replaced with a femoral vein graft in 25 mongrel dogs. After 3
months, grafts were explanted in 5 dogs (control grafts), and the remaining 20 dogs underwent femoral artery ligation
to create a thrombosed graft. Of the 20 grafts, 5 were explanted at 3 days after ligation (group I-3) and 5 were explanted
at 5 days after ligation (group I-5). Of the remaining 10 grafts, 5 underwent thrombectomy at 3 days after ligation (group
II-3) and 5 underwent thrombectomy at 5 days after ligation, and were reimplanted into the left femoral artery, then
explanted 28 days after reimplantation. The grafts were assessed with immunohistochemistry and prostaglandin (PG) I2
assay (6-keto-PGI1).
Results:Of the 25 grafts, occlusion recurred in 3 in group II-5 within 28 days after reimplantation. There were significant
differences between group I-5 and group I-3 or control grafts for percentage of areas positive for -actin, total number
of cells per field, and proliferating cell nuclear antigen (PCNA)–positive cells in layer of thickened intima and atrophied
media (I/M), and for total cell and PCNA- positive cell numbers per field in the adventitia. Mean 6-ketoPGF1 was 40
 14.1 pg/mg/min in control dogs, 84  18.9 pg/mg/min in group I-3, and 15.4  7.7 pg/mg/min in group I-5,
demonstrating a significant reduction in group I-5 (P  .009).
Conclusion: Graft wall cell viability and PGI2 production in thrombosed vein grafts are well preserved for up to 3 days.
Therefore graft salvage operations no later than 3 days after thrombotic occlusion may provide acceptable long-term
patency of salvaged grafts. (J Vasc Surg 2003;38:305-12.)
Vein grafts have been widely used for bypass grafting in
small-caliber arteries, and their excellent patency is attrib-
uted to the antithrombogenic function of live cells in the
graft wall. To preserve this cell function, various techniques
for graft preparation have been introduced; however, vein
graft patency rate for infrainguinal or coronary artery by-
pass grafts is only about 70% at 5 years.1-3 The main cause
of graft failure is graft stenosis due to progressive intimal
hyperplasia, which frequently results in thrombotic occlu-
sion despite intensive graft surveillance.4 Patency of throm-
bosed vein grafts frequently can be restored with throm-
bectomy or direct thrombolysis, with or without revision
procedures; however, the patency rate of the salvaged grafts
is poor, as low as 19% to 31% at 2 years after salvage
operation.5-7 Nackman et al8 found that older grafts
achieved longer patency after direct graft thrombolysis,
likely because of reflection of their qualitative adequacy as
conduits. In vein grafts older than 1 year selected for this
therapy, a 2-year primary patency rate of 49% was pre-
dicted. Nevertheless, this improved patency rate for the
selected graft group is still insufficient to explain the poor
results of grafts after thrombectomy, suggesting the pres-
ence of more relevant factors. Graft thrombosis may induce
inflammatory reactions and subsequent degeneration of
viable components in the graft wall, and the level of degen-
erative changes may affect graft patency after salvage oper-
ation.
To clarify the mechanism for poor patency and the time
limit for successful salvage operation in thrombosed grafts,
we investigated the time course of biologic degenerative
changes in thrombosed vein grafts and their influence on
graft patency after salvage operation.
MATERIALS AND METHODS
Twenty-five randomly selected mongrel dogs of both
sexes, weighing 12 to 15 kg, were used in the study. Their
care and use complied with the Principles of Laboratory
Animal Care formulated by the National Society for Med-
ical Research and with the Guide for Care and Use of
Laboratory Animals, Institute of Laboratory Animal Re-
sources, Commission on Life Sciences, National Research
Council.
All 25 animals were anesthetized with intravenous thia-
mylal sodium. Endotracheal tubes were inserted, and the
lungs were ventilated with 33% oxygen. With sterile surgi-
cal technique, the right femoral artery and vein were dis-
sected. After intravenous administration of heparin (100
From the Departments of Surgery and Pathology, Asahikawa Medical
University, Asahikawa, Japan.
Competition of interest: none.
Reprint requests: Tadahiro Sasajima, MD, PhD, Department of Surgery,
AsahikawaMedical University, 2-3MidorigaokaHigashi, Asahikawa 078-
8307, Japan. (e-mail: sasajit@asahikawa-med.ac.jp).
Copyright © 2003 by The Society for Vascular Surgery and The American




IU/kg), a 5 cm length of femoral vein was harvested for use
as a graft. Both ends of the graft were removed for histo-
logic analysis, and the femoral artery was replaced with the
vein graft in reverse fashion, using continuous 7-0 polypro-
pylene sutures. After 3 months, 5 of the 25 grafts were
explanted for use as control grafts; the remaining 20 dogs
underwent femoral artery ligation distal to the graft to
thrombose the grafts. Of the 20 thrombosed grafts, 5 were
explanted at 3 days after ligation (group I-3) and 5 were
explanted at 5 days after ligation (group I-5), and were
subjected to histologic analysis, immunohistochemistry,
and prostaglandin I2 (PGI2) assay. Of the 10 remaining
grafts, at 3 days (group II-3) or 5 days (group II-5) after
thrombotic occlusion, thrombectomy was performed three
times in each graft via arteriotomy distal to the graft with a
3F balloon catheter (Fogarty arterial embolectomy cathe-
ter; Baxter Healthcare, Deerfield, Ill). The thrombecto-
mized grafts were immediately harvested for sampling for
scanning electron microscopy, and autogeneously reim-
planted into the contralateral femoral artery with end-to-
end anastomosis. These grafts were explanted 28 days after
reimplantation and subjected to histologic analysis and
scanning electron microscopy.
Neither antiplatelet agents nor anticoagulants were
given during the observation period. At graft retrieval, the
animals were again anesthetized, and graft patency was
assessed with palpation of the distal femoral arteries. After
heparinization, a euthanasia solution was administered in-
travenously. The grafts, including both anastomoses, were
carefully harvested, and two 1 cm long segments were cut
from the graft. One segment was fixed with 10% buffered
formalin; the other segment was longitudinally opened,
rinsed with heparinized saline solution for removal of
thrombi, and, after excision of excessive surrouding tissue,
prepared for PGI2 assay.
Table I. Quantitative cell analysis in vein grafts after thrombotic occlusion
Femoral










(n  2) P*
Intima/media
Thickness (m) 13.6  4.4 51.9  11.6 51.3  10.4 59.8  22.5 233.8  51.8 382.5  46.0 .602
%--Actin (%) 54.2  20.0 40.6  21.9 6.6  2.9 47.5  21.8 3.8  0.7 .009
Total cells 45.8  5.3 32.8  9.3 39.9  3.1 11.4  7.9 29.2  8.6 26.5  10.6 .009
Proliferating cells 17.9  10.0 29.2  11.5 5.8  3.9 14.2  6.9 10.5  2.1 .016
Apoptotic cells 9.0  5.3 9.6  3.2 8.3  6.2 7.8  4.4 17.5  0.7 .602
Macrophages 0 2.7  2.4 0.4  0.3 0 0 .028
Adventitia
Total cells 20.2  6.5 20.3  3.6 23.8  9.7 10.7  7.4 27.0  10.7 17.5  9.2 .021
Proliferating cells 11.9  4.8 12.6  5.6 4.0  2.5 10.2  4.6 9.0  5.7 .028
Apoptotic cells 8.1  2.8 7.6  2.0 8.4  6.2 7.2  1.8 18.0  1.4 .754
Macrophages 0 2.7  1.8 0.4  0.2 0 0 .076
Surrounding tissue
Macrophages 0 2.5  1.0 2.1  1.1 0.8  1.8 5.5  0.7 .465
No. of cells expressed as cell number per field of 50  200 m2.
*Group I-3 vs group I-5.
Fig 1. Immunohistochemistry for macrophages in thrombosed
grafts. Note moderate infiltration of macrophages (arrows) both
inside and outside of 3-day grafts. (Mouse anti-human CD68
staining method; original magnification, 30.)
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Histologic analysis, immunohistochemistry, and
scanning electron microscopy. Specimens for histologic
anaysis and immunohistochemistry were cross-sectioned
and embedded in paraffin. Hematoxylin-eosin, Verhoeff–
van Gieson, and Masson trichrome staining methods were
used to identify the three vessel layers; vascular smooth
muscle cells, proliferating cells, apoptotic cells, and macro-
phages were identified at immunohistochemistry with
monoclonal mouse anti-human smooth muscle actin anti-
body 1A4 (-SM actin, 1:100; DAKO, Carpinteria, Calif),9
monoclonal mouse anti-proliferating cell nuclear antigen
(PCNA)(PC-10, 1:200; DAKO),10 single-stranded DNA
(ssDNA) staining with goat anti-rabbit immunogloblin
(DAKO ENVISION, 1:200; DAKO),11 and mouse anti-
human CD68 (KP1, prediluted; DAKO),12 respectively.
Canine inguinal lymph nodes and femoral arteries 24 hours
after harvesting were used as negative and positive controls
for ssDNA, PCNA, and CD68, or -SM actin. In ssDNA
staining, hematoxylin was used as counterstain to detect
ssDNA-negative cells.
The specimens for scanning electron microscopy were
fixed with 1% glutaraldehyde, dehydrated in a graded t-
butyl alcohol series, freeze-dried, and coated with platinum
before examination.
Histologic and morphometric quantitative analy-
sis. Numbers of cell nuclei were microscopically counted
in a complex layer of thickened intima and atrophied media
(I/M) and in the adventitia. Degeneration of graft wall
cells was assessed with PCNA-positive cell numbers,
apoptotic cell numbers, and ratio of -SM actin–positive
area to total area (%–-actin positive area), which was
measured with planimetry with a computerized morpho-
metric analysis system (Apple, Cupertino, Calif), with
the public domain program Image (Research Service
Branch, National Institutes of Health, Bethesda, Md).
All measurements were performed in one visual field with
50  200 m within the I/M along the luminal surface
or within the adventitia along the external elastic lamina.
These quantitative data were represented by an average
of three randomly selected microscopic visual fields in
each section.
Radioimmunoassay of PGI2 production. PGI2
production of vein graft specimens was measured with
radioimmunoassay as its stable metabolite, 6-keto-prosta-
Fig 2. Immunohistochemistry results for -actin positive cells in thrombosed grafts. A, Three-day graft shows no
significant decrease in positive cell area when compared with control graft.B,Note obvious decrease in positive cell area
in 5-day graft.
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glandin F1 (6-keto-PGF1), (
125I-6-keto-PGF1 kit; New
England Nuclear Research Products, Boston, Mass) in an
unstimulated condition. Each specimen was placed in an
incubation well containing 1.0 mL of Tris sodium chloride
buffer (pH 7.4) and incubated in a shaker for 5 minutes at
37°C. After incubation, each specimen was quickly re-
moved from the incubation well, and indomethacin (200
g/mL) was added. The remaining fluid was pipetted into
a polypropylene tube and frozen at 80°C for later assay;
and the specimen removed was placed in a heat chamber for
24 hours at 100°C, and the dry weight was obtained.
Values for 6-keto-PGF1 were expressed as picograms of
immunoreactive 6-keto-PGF1 per milligram of dried vein
tissue per minute.
Statistical analysis
Data were analyzed with StatView software (Avacus
Concepts, Berkeley, Calif) and are presented as mean  1
SD. The Kruskal-Wallis test (nonparametric analysis of
variance) and subsequent multiple comparisons with the
Mann-Whitney U test or X2 test were used to determine
differences of quantitative data between groups. P  .05
was considered statistically significant.
RESULTS
Graft patency Patency of the 25 grafts was assessed
with palpation at the groin. All 5 control grafts, all 10 grafts
in group I before ligation, and all 5 grafts in group II-3
were patent, whereas 3 of 5 grafts in group II-5 had
occluded again within 28 days after reimplantation.
Histologic analysis, immunohistochemistry, and
morphometric analysis
At histologic analysis, before implantation the femoral
vein grafts had an endothelial lining, a thin medial layer
with average thickness of 13.6  4.4 m, and a relatively
thick adventitia with a thickness of 50 to 150 m. Average
number of cells in the media and adventitia was 45.8 5.3
and 20.2  6.5 per field, respectively.
Control grafts. Graft reendothelialization was com-
plete within 3 months. Thickened intima associated with
atrophiedmedia, with average thickness of 51.9 11.6m
Fig 3. Immunohistochemistry results for proliferating cell nuclear antigen (PCNA)–positive cells (arrows) in throm-
bosed grafts. A, Control graft. B, Note significant increase in PCNA-positive cells in 3-day graft. C, There is obvious
decrease in PCNA cells in 5-day graft. (PCNA staining method; original magnification, 60.) Continued.
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(range, 33-64 m), was a common sequela. The %–-actin
positive area in the I/M and the number per field of total
cells, PCNA-positive cells, and apoptotic cells in the I/M
and the adventitia are given in Table I. Neither macro-
phages nor other types of white blood cells were recognized
at CD68 and hematoxylin-eosin staining.
Group I. There were no obvious differences in graft
connective tissue when compared with control grafts. At
microscopy, inflammatory cells, more than 80% of which
were macrophages, moderately infiltrated around the
graft area and luminal thrombus in the 5-day and 3-day
grafts (Fig 1). Significant decreases in -actin positive
area and in number of total cells and PCNA- positive
cells were recognized in the 5-day grafts compared with
the 3-day grafts or control grafts (Figs 2 and 3). Signif-
icant numbers of apoptotic cells were constantly recog-
nized in all grafts, including control grafts (Fig 4). The
%–-actin positive area of the I/M and the number per
field of total cells, PCNA-positive cells, apoptotic cells,
and macrophages for both the I/M and adventitia in
groups I-3 and I-5 are given in Table I. All values showed
significant differences between group I-5 and group I-3
or control grafts.
Group II. The %–-actin positive area of the I/M
and the number per field of total cells, PCNA-positive
cells, apoptotic cells, and macrophages for both the I/M
and adventitia in groups II-3 and II-5 are given in Table
I. At scanning electron microscopy the thrombecto-
mized grafts before reimplantation showed a rough fi-
brous denuded luminal surface, whereas the surfaces of
all of the 5 grafts in group II-3 were covered with a
confluent endothelial cell lining (Fig 5). The 2 patent
grafts in group II-5 also had endothelial cells; however,
coverage was sparse and incomplete, and histologic anal-
ysis revealed severe intimal hyperplasia, compared with
the grafts in group II-3.
Prostacyclin production
Mean values for 6-keto-PGF1 in the control grafts and
groups I-3 and I-5 are given Table II. These values reveal
dominant PGI2 hyperproduction in the 3-day grafts and
significant reduction in the 5-day grafts (P  .009). The
dominant PGI2 production in the 3-day grafts was signifi-
cantly higher, even when compared with that in control
grafts (P  .016), testifying to satisfactory reimplantation
results in grafts that underwent thrombectomy 3 days after
occlusion.
DISCUSSION
Cultured human arterial smooth muscle cells synthe-
size PGI2;
13 therefore the medial vascular smooth mus-
cle cells may have an important role in maintaining
patency of vein grafts by their significant production of
PGI2.
14,15 Degenerative changes in the graft wall after
thrombotic occlusion should be evaluated in each vessel
layer; however, the medial layer of the canine femoral
vein is very thin compared with human saphenous vein,
and various levels of intimal thickening were associated
with marked medial atrophy in the grafts 3 months after
implantation. Thus quantitative assessment was per-
formed for the I/M complex layer and the adventitia.
After thrombotic occlusion, moderate numbers of
macrophages surrounded the grafts, both from outside
and from the luminal thrombus, and a few macrophages
infiltrated the wall. Viability of the graft wall cells seemed
to be well preserved in the 3-day grafts; however, a
marked decrease in cell numbers occurred between day 3
and day 5 after thrombotic occlusion. In the thrombosed
grafts, two types of cell death were observed: apoptosis
and necrosis or karyolysis. To assess apoptosis we used
the ssDNA method, which has great value for identifica-
tion of apoptosis and is useful for differentiation of
apoptosis and necrosis.16 However, there are no specific
measures for direct identification of necrosis; therefore
we estimated the occurrence of necrosis by decrease in
total cell number at hematoxylin-eosin staining. In the 5-
day grafts, apoptotic cell numbers showed no changes
compared with the 3-day or control grafts, whereas not
Fig 3. (Continued.)
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only total cells but also PCNA-positive and -actin pos-
itive cells markedly decreased in number compared with
the 3-day grafts. These findings suggest that necrosis is
the probable main mechanism of cell death in the throm-
bosed graft wall and that most of the killed cells were
-actin positive cells, because of their marked reduction
in the 5-day grafts.
PGI2 assay revealed that hyperproduction of PGI2 oc-
curred in the 3-day grafts. Thrombosed grafts sustained a
moderate level of macrophage infiltration. Macrophages
produce interleukin (IL)–117 and IL-6,18 and IL-1 is a
potent vasodilator, causing prolonged induction of PGI2
and cyclic adenosine monophosphate synthesis in human
vascular smooth muscle cells.19 In the 3-day grafts, more
than 70% of the graft wall cells still lived, and the graft wall
was surrounded with significant numbers of macrophages.
The IL-1 produced by macrophages may stimulate these
live graft wall cells, resulting in hyperproduction of PGI2.
Macrophage infiltration still continued in the 5-day grafts;
however, PGI2 production was significantly reduced be-
cause of the marked decrease in viable cells. This appears to
explain the presence of a substantial gap in biologic func-
tion between the 3-day and 5-day grafts.
At scanning electron microscopy no endothelial cells
were found in the luminal surfaces of the grafts immediately
after thrombectomy; however, after reimplantation all of
the 3-day grafts and 2 patent 5-day grafts were covered with
endothelial cells, though coverage was incomplete in the
5-day grafts. At histologic analysis the level of intimal
thickening in these 2 patent 5-day grafts was higher than
that in the 3-day grafts, probably because of the incomplete
endothelial coverage. The complete endothelial cell lining
in the 3-day grafts suggests that vein grafts thrombecto-
mized within 3 days after thrombotic occlusion may
achieve a long-term patency rate comparable to that of
primary vein grafts.
CONCLUSION
PGI2 production of vein grafts is still well preserved 3
days after thrombotic occlusion; however, marked cell de-
generation occurs thereafter, and production declines as a
result of cell death. Therefore, to obtain acceptable long-
Fig 4. Immunohistochemistry results for apoptotic cells in 3-day grafts. There are no significant changes in apoptotic
cell numbers (arrows) between control grafts (A), 3-day grafts (B), or 5-day grafts (C). (ssDNA staining method;
original magnification, 60.) Continued.
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term patency of salvaged grafts, graft salvage operation
should be performed within 3 days after occlusion.
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